Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-PD-L1 Antibody (2I950) is an antibody targeting PD-L1. Anti-PD-L1 Antibody (2I950) can be used in ELISA, IHC, FCM.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
50 μL | $207 | 7-10 days | |
100 μL | $347 | 7-10 days |
Description | Antibody Type: Recombinant Mouse Monoclonal Application: ELISA, IHC, FCM Reactivity: Human |
Alias | PD-L1B7 homolog 1, PD-L1, PDL1, PDCD1LG1, PDCD1L1, CD274, B7-H1, B7H1, B7-H |
Ig Type | Mouse IgG2a |
Clone | 2I950 |
Reactivity | Human |
Verified Activity | 1. IHC image of TMAH-00186 diluted at 1:100 and staining in paraffin-embedded human lung cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-Mouse IgG labeled by HRP and visualized using 0.05% DAB. 2. Overlay Peak curve showing Hela cells surface stained with TMAH-00186 (red line) at 1:100. Then 10% normal goat serum was Incubated to block non-specific protein-protein interactions followed by the antibody (1µg/1*10^6 cells) for 45 min at 4°C. The secondary antibody used was FITC-conjugated Goat Anti-Mouse IgG(H+L) at 1/200 dilution for 35 min at 4°C. Isotype control antibody (green line) was mouse IgG1 (1µg/1*10^6 cells) used under the same conditions. Acquisition of >10,000 events was performed. |
Application | ELISA, IHC, FCM |
Recommended Dose | IHC:1:20-1:200; FCM:1:20-1:200. |
Antibody Type | Monoclonal |
Subcellular Localization | Cell membrane; Single-pass type I membrane protein. Early endosome membrane; Single-pass type I membrane protein. Recycling endosome membrane; Single-pass type I membrane protein.; [Isoform 1]: Cell membrane; Single-pass type I membrane protein.; [Isoform 2]: Endomembrane system; Single-pass type I membrane protein. |
Construction | Recombinant Antibody |
Purification | Affinity-chromatography |
Appearance | Liquid |
Formulation | Preservative: 0.03% Proclin 300. Constituents: 50% Glycerol, 0.01M PBS, PH 7.4. |
Research Background | Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy. |
Conjucates | Unconjugated |
Immunogen | Recombinant Protein: Human CD274 Protein |
Antigen Species | Human |
Gene ID | 29126 |
Uniprot ID | |
Biology Area | Cancer, Immunology |
Stability & Storage | Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.